Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 71.28 USD 0.32% Market Closed
Market Cap: 11.3B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Bio-Techne Corp
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bio-Techne Corp
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Bio-Techne Corp
NASDAQ:TECH
Long-Term Debt
$319m
CAGR 3-Years
-1%
CAGR 5-Years
-8%
CAGR 10-Years
47%
Thermo Fisher Scientific Inc
NYSE:TMO
Long-Term Debt
$31.2B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Long-Term Debt
$16.3B
CAGR 3-Years
-12%
CAGR 5-Years
0%
CAGR 10-Years
19%
Mettler-Toledo International Inc
NYSE:MTD
Long-Term Debt
$1.9B
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
18%
Agilent Technologies Inc
NYSE:A
Long-Term Debt
$2.1B
CAGR 3-Years
-8%
CAGR 5-Years
11%
CAGR 10-Years
0%
IQVIA Holdings Inc
NYSE:IQV
Long-Term Debt
$12.3B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
20%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.3B USD
Industry
Life Sciences Tools & Services

Bio-Techne Corp. stands at the forefront of scientific progress, intertwining innovation with essential biotechnology solutions. Founded in 1976 and headquartered in Minneapolis, the company has evolved from its roots in producing protein research reagents to a diversified powerhouse, supporting the life sciences and clinical diagnostics sectors. Bio-Techne's expansive portfolio encompasses cutting-edge tools and technologies allowing researchers to delve deeper into cellular analysis, gene expression, and molecular diagnostics. With brands like R&D Systems, Novus Biologicals, and ProteinSimple under its belt, the company empowers scientists worldwide to unlock new discoveries, simulate complex biological processes, and ultimately contribute to advancements in healthcare and life sciences. For investors, Bio-Techne presents a compelling opportunity as it operates in a rapidly growing market fueled by increasing demand for precision medicine and advanced research capabilities. The company has demonstrated robust financial performance, marked by consistent revenue growth and healthy profit margins, driven by its commitment to research and development. As Bio-Techne continues to expand its product offerings and enhance its technological capabilities through strategic acquisitions, it stands poised to capture greater market share and drive shareholder value. With a seasoned management team guided by a focus on innovation and customer-centric solutions, Bio-Techne is not just responding to market trends but actively shaping the future of biotechnology.

TECH Intrinsic Value
54.19 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Bio-Techne Corp's Long-Term Debt?
Long-Term Debt
319m USD

Based on the financial report for Jun 30, 2024, Bio-Techne Corp's Long-Term Debt amounts to 319m USD.

What is Bio-Techne Corp's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
47%

Over the last year, the Long-Term Debt growth was -9%. The average annual Long-Term Debt growth rates for Bio-Techne Corp have been -1% over the past three years , -8% over the past five years , and 47% over the past ten years .

Back to Top